Omnicell (NASDAQ:OMCL) Trading Up 4.7% – Here’s Why

Omnicell, Inc. (NASDAQ:OMCL)’s stock price traded up 4.7% on Monday . The company traded as high as $34.88 and last traded at $34.62. 429,069 shares were traded during mid-day trading, a decline of 35% from the average daily volume of 663,429 shares. The stock had previously closed at $33.08.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on OMCL shares. Zacks Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Wall Street Zen upgraded shares of Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Wells Fargo & Company lowered their target price on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Finally, KeyCorp reissued an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Omnicell presently has an average rating of “Moderate Buy” and a consensus target price of $57.86.

Omnicell Stock Up 5.2%

The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. The firm’s 50-day moving average price is $39.80 and its 200 day moving average price is $39.35. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of 41.44, a price-to-earnings-growth ratio of 0.83 and a beta of 0.98.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.94 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The business had revenue of $312.21 million for the quarter, compared to analyst estimates of $310.21 million. During the same quarter last year, the company earned $0.45 earnings per share. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Sell-side analysts expect that Omnicell, Inc. will post 1.41 EPS for the current year.

Institutional Trading of Omnicell

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Corient Private Wealth LP lifted its position in Omnicell by 46.7% during the second quarter. Corient Private Wealth LP now owns 62,809 shares of the company’s stock valued at $2,608,000 after buying an additional 20,000 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Omnicell in the second quarter worth $340,000. California State Teachers Retirement System increased its position in shares of Omnicell by 4,074.3% in the second quarter. California State Teachers Retirement System now owns 2,100,621 shares of the company’s stock worth $87,218,000 after acquiring an additional 2,050,298 shares in the last quarter. Nykredit A S purchased a new position in shares of Omnicell in the 2nd quarter valued at $26,000. Finally, Moore Capital Management LP purchased a new position in shares of Omnicell in the 2nd quarter valued at $3,644,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.